The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Co-Delivery of siRNA and An Anticancer Drug for Treatment of Multidrug-Resistant Cancer
Open accessAbstract
AIMS: To develop a novel nanomedicine approach for the treatment of multidrug-resistant (MDR) cancer by combining an anticancer drug and suppressors of cellular resistance within one multifunctional nanocarrier-based delivery system (NDS). MATERIALS & METHODS: The NDS consisted of cationic liposomes (carrier, 100-140 nm), doxorubicin (DOX, anticancer drug), siRNA targeted to MRP1 and BCL2 mRNA (suppressors of pump and nonpump cellular-resistance, respectively). The resulting approximately 500 nm complex has a zeta potential of +4 mV. RESULTS & DISCUSSION: The NDS provides an effective co-delivery of DOX and siRNA as well as cell-death induction and suppression of cellular resistance in MDR lung cancer cells. CONCLUSION: We demonstrate NDS-enhanced efficiency of chemotherapy to a level that cannot be achieved by applying its components separately.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death
Oltval, Z. N., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)90509-o · Cited by 6,003
The Bcl-2 Protein Family: Arbiters of Cell Survival
Adams, J. M., & Cory, S. (1998) · Science · doi:10.1126/science.281.5381.1322 · Cited by 5,332
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
Lowe, S. W., & Lin, A. W. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.485 · Cited by 1,876
Dysregulation of Apoptosis in Cancer
Reed, J. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2941 · Cited by 987
Polymer–drug conjugates: Progress in polymeric prodrugs
Khandare, J., & Minko, T. (2006) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2005.09.004 · Cited by 639
Self-citationPolymeric nanoparticles for cancer therapy
Parveen, S., & Sahoo, S. K. (2008) · Journal of Drug Targeting · doi:10.1080/10611860701794353 · Cited by 427
Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide
Dharap, S. S., Wang, Y., Chandna, P., Khandare, J. J., Qiu, B., Gunaseelan, S., Sinko, P. J., Stein, S., Farmanfarmaian, A., & Minko, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504274102 · Cited by 340
Self-citationWu, H., Hait, W. N., & Yang, J. (2003) · PubMed · Cited by 289
Holinger, E. P., Chittenden, T., & Lutz, R. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.19.13298 · Cited by 254
Cited by
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Nanotechnology in Drug Delivery and Tissue Engineering: From Discovery to Applications
Shi, J., Votruba, A. R., Farokhzad, O. C., & Langer, R. (2010) · Nano Letters · doi:10.1021/nl102184c · Cited by 1,612
Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00193 · Cited by 1,451
Meng, H., Liong, M., Xia, T., Li, Z., Ji, Z., Zink, J. I., & Nel, A. E. (2010) · ACS Nano · doi:10.1021/nn100690m · Cited by 902
Synergistic effect of chemo-photothermal therapy using PEGylated graphene oxide
Zhang, W., Guo, Z., Huang, D., Liu, Z., Guo, X., & Zhong, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.071 · Cited by 891
Cyclodextrin-based supramolecular systems for drug delivery: Recent progress and future perspective
Zhang, J., & Ma, P. X. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.05.001 · Cited by 836
Nanostructured lipid carriers: Promising drug delivery systems for future clinics
Beloqui, A., Solinís, M. Á., Rodríguez-Gascón, A., Almeida, A. J., & Préat, V. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.09.004 · Cited by 769
Nanomedicine therapeutic approaches to overcome cancer drug resistance
Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.019 · Cited by 733
“Further, liposomal anti-MRP-1 and anti-Bcl2 siRNA in combination with Doxorubicin were used to suppress pump and non-pump mediated cellular resistance and to cause death in MDR lung cancer cells [116].”
MethodNanoparticle-based combination therapy toward overcoming drug resistance in cancer
Hu, C.-M. J., & Zhang, L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.008 · Cited by 686
Wang, H., Zhao, Y., Wu, Y., Hu, Y.-L., Nan, K., Nie, G., & Chen, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.032 · Cited by 603
Meng, H., Mai, W. X., Zhang, H., Xue, M., Xia, T., Lin, S., Wang, X., Zhao, Y., Ji, Z., Zink, J. I., et al. (2013) · ACS Nano · doi:10.1021/nn3044066 · Cited by 575
Nanoparticle-assisted Combination Therapies for Effective Cancer Treatment
Hu, C.-M. J., Aryal, S., & Zhang, L. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.13 · Cited by 564
Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.003 · Cited by 504
PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy
Abedi-Gaballu, F., Dehghan, G., Ghaffari, M., Yekta, R., Abbaspour-Ravasjani, S., Baradaran, B., Ezzati Nazhad Dolatabadi, J., & Hamblin, M. R. (2018) · Applied Materials Today · doi:10.1016/j.apmt.2018.05.002 · Cited by 487
Liang, C., Xu, L., Song, G., & Liu, Z. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00458j · Cited by 435
Taratula, O., Kuzmov, A., Shah, M., Garbuzenko, O. B., & Minko, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.018 · Cited by 416
Self-citationSupramolecular cancer nanotheranostics
Zhou, J., Rao, L., Yu, G., Cook, T. R., Chen, X., & Huang, F. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00011f · Cited by 411
Sun, T.-M., Du, J.-Z., Yao, Y.-D., Mao, C.-Q., Dou, S., Huang, S.-Y., Zhang, P.-Z., Leong, K. W., Song, E.-W., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn103349h · Cited by 406
Nanocarrier-based systems for targeted and site specific therapeutic delivery
Majumder, J., Taratula, O., & Minko, T. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.07.010 · Cited by 394
Self-citationGandhi, N. S., Tekade, R. K., & Chougule, M. B. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.001 · Cited by 394
Liposomal Delivery Systems: Design Optimization and Current Applications
Abu Lila, A. S., & Ishida, T. (2017) · Biological & Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00624 · Cited by 382
Ganesh, S., Iyer, A. K., Morrissey, D. V., & Amiji, M. M. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.077 · Cited by 362
Multifunctional Nanoparticles for Combined Doxorubicin and Photothermal Treatments
Park, H., Yang, J., Lee, J., Haam, S., Choi, I.-H., & Yoo, K.-H. (2009) · ACS Nano · doi:10.1021/nn900215k · Cited by 359
Nanotechnology approaches for inhalation treatment of lung diseases
Kuzmov, A., & Minko, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.024 · Cited by 352
Self-citationRole of integrated cancer nanomedicine in overcoming drug resistance
Iyer, A. K., Singh, A., Ganta, S., & Amiji, M. M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.012 · Cited by 343
Nanopreparations to overcome multidrug resistance in cancer
Patel, N. R., Pattni, B. S., Abouzeid, A. H., & Torchilin, V. P. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.004 · Cited by 333
Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance
Creixell, M., & Peppas, N. A. (2012) · Nano Today · doi:10.1016/j.nantod.2012.06.013 · Cited by 331
Fernandez-Fernandez, A., Manchanda, R., & McGoron, A. J. (2011) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-011-9383-z · Cited by 330
Taratula, O., Garbuzenko, O. B., Kirkpatrick, P., Pandya, I., Savla, R., Pozharov, V. P., He, H., & Minko, T. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.06.019 · Cited by 328
Self-citationNanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress
Dong, X., & Mumper, R. J. (2010) · Nanomedicine · doi:10.2217/nnm.10.35 · Cited by 317
Liposome-based drug co-delivery systems in cancer cells
Zununi Vahed, S., Salehi, R., Davaran, S., & Sharifi, S. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.11.073 · Cited by 307
Co-delivery of siRNAs and anti-cancer drugs using layered double hydroxide nanoparticles
Li, L., Gu, W., Chen, J., Chen, W., & Xu, Z. P. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.095 · Cited by 304
Nanotechnology applied to overcome tumor drug resistance
Gao, Z., Zhang, L., & Sun, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.051 · Cited by 303
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
Application of Nanotechnology in Drug Delivery
(2014) · InTech eBooks · doi:10.5772/57028 · Cited by 266
Multidrug resistance: Physiological principles and nanomedical solutions
Kunjachan, S., Rychlik, B., Storm, G., Kiessling, F., & Lammers, T. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.018 · Cited by 259
Nanodrug delivery in reversing multidrug resistance in cancer cells
Yergeri, M., Kapse-Mistry, S., Srivastava, R., & Govender, T. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00159 · Cited by 255
Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery
Vaughan, H. J., Green, J. J., & Tzeng, S. Y. (2020) · Advanced Materials · doi:10.1002/adma.201901081 · Cited by 255
Pluronics and MDR reversal: an update
Alakhova, D. Y., & Kabanov, A. V. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500298q · Cited by 224
Sabhachandani, P., Motwani, V., Cohen, N., Sarkar, S., Torchilin, V., & Konry, T. (2016) · Lab on a Chip · doi:10.1039/c5lc01139f · Cited by 193
Nanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178
“While “naked”, chemically modified siRNA has shown efficacy in certain physiological settings such as the brain and the lung, an additional delivery system is still required to maintain the RNA stability, improve cellular uptake and facilitate transfection [40, 62].”
BackgroundSong, X., Zhang, R., Liang, C., Chen, Q., Gong, H., & Liu, Z. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.04.001 · Cited by 101
Wu, Y., Zhang, Y., Zhang, W., Sun, C., Wu, J., & Tang, J. (2016) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2015.11.041 · Cited by 100
Drug Targeting Strategies Based on Charge Dependent Uptake of Nanoparticles into Cancer Cells
Saadat, M., Zahednezhad, F., Zakeri-Milani, P., Reza Heidari, H., Shahbazi-Mojarrad, J., & Valizadeh, H. (2019) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps30318 · Cited by 88
Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs
Huang, W., Chen, L., Kang, L., Jin, M., Sun, P., Xin, X., Gao, Z., & Bae, Y. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.004 · Cited by 77
Nanodelivery Systems for Nucleic Acid Therapeutics in Drug Resistant Tumors
Iyer, A. K., Duan, Z., & Amiji, M. M. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500024p · Cited by 55
Metadata
- Authors
- Saad, M., Garbuzenko, O. B., & Minko, T.
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2008-11-24
- Volume
- 3
- Issue
- 6
- Pages
- 761-776
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2150702593
- Cited by
- 367
- References
- 48
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.